A single-center, exploratory study combined second-line chemotherpy with third-line drugs, apatinib and anti-PD-1 antibody in advanced gastric cancer patients
Latest Information Update: 20 Jul 2021
At a glance
- Drugs Irinotecan (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology